Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Assets (2018 - 2025)

10x Genomics (TXG) has disclosed Assets for 8 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Assets rose 13.36% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, up 13.36% year-over-year, with the annual reading at $1.0 billion for FY2025, 13.36% up from the prior year.
  • Assets hit $1.0 billion in Q4 2025 for 10x Genomics, up from $1.0 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.0 billion in Q4 2025 to a low of $903.4 million in Q1 2025.
  • Historically, Assets has averaged $977.5 million across 5 years, with a median of $984.8 million in 2023.
  • Biggest five-year swings in Assets: soared 67.74% in 2021 and later decreased 8.99% in 2024.
  • Year by year, Assets stood at $1.0 billion in 2021, then rose by 1.0% to $1.0 billion in 2022, then decreased by 6.2% to $965.1 million in 2023, then dropped by 4.82% to $918.6 million in 2024, then increased by 13.36% to $1.0 billion in 2025.
  • Business Quant data shows Assets for TXG at $1.0 billion in Q4 2025, $1.0 billion in Q3 2025, and $980.0 million in Q2 2025.